STAT

Opinion: The NIH needs to become leaner and more innovative. Here’s how to do that

There's no question that the NIH could be a leaner and more innovative organization. Here's how to do it.

Worried about America’s biomedical research enterprise, academics have persistently sounded the alarm over slow growth in the National Institutes of Health budget. The Trump administration responded to those concerns in its 2018 proposed NIH budget by recommending a 22 percent budget cut and a reduction in support for indirect costs. While those cuts never came to pass, they marked a manifestation of political will to examine spending at the NIH.

There’s no question that the NIH could be a leaner and more innovative organization. But that would require elemental reforms in how it supports indirect costs (more on those in a minute) and its reliance on study sections to review grant proposals.

We propose two key reforms and offer a model that could reinvigorate innovation at the NIH while also funding “more for less.”

Reform support for indirect costs

Most NIH grant include salaries, travel, equipment and supplies, and the like that directly support a project or activity. , also known as facilities and administrative costs, such as buildings, maintenance, and administration.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks